FDA Determines Regulatory Review Period for FOLOTYN Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of FOLOTYN, a human drug product, as required by law. This determination was made following a submission to the Director of Patents and Trademarks at the US Department of Commerce.